CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade Idera Pharma - IDRA CFD

0.40
24.53%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025457%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003235%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Aceragen Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.53
Open* 0.46
1-Year Change* -28.13%
Day's Range* 0.4 - 0.46
52 wk Range 0.30-0.95
Average Volume (10 days) 76.59K
Average Volume (3 months) 2.20M
Market Cap 21.41M
P/E Ratio -100.00K
Shares Outstanding 62.36M
Revenue N/A
EPS -0.34
Dividend (Yield %) N/A
Beta 1.43
Next Earnings Date Mar 29, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 17, 2023 0.40 -0.06 -13.04% 0.46 0.47 0.40
Jan 13, 2023 0.53 0.00 0.00% 0.53 0.53 0.52
Jan 12, 2023 0.53 0.02 3.92% 0.51 0.54 0.50
Jan 11, 2023 0.48 0.04 9.09% 0.44 0.49 0.41
Jan 10, 2023 0.44 -0.17 -27.87% 0.61 0.64 0.41
Jan 9, 2023 0.64 -0.04 -5.88% 0.68 0.68 0.63
Jan 6, 2023 0.66 0.03 4.76% 0.63 0.69 0.63
Jan 5, 2023 0.63 0.12 23.53% 0.51 0.65 0.51
Jan 4, 2023 0.53 0.10 23.26% 0.43 0.53 0.43
Jan 3, 2023 0.43 0.03 7.50% 0.40 0.45 0.39
Nov 15, 2022 0.38 -0.02 -5.00% 0.40 0.40 0.38
Nov 11, 2022 0.38 0.00 0.00% 0.38 0.38 0.38
Nov 10, 2022 0.38 0.00 0.00% 0.38 0.38 0.38
Nov 8, 2022 0.39 -0.02 -4.88% 0.41 0.41 0.39
Nov 7, 2022 0.40 0.00 0.00% 0.40 0.41 0.39
Nov 4, 2022 0.39 -0.01 -2.50% 0.40 0.40 0.39
Nov 3, 2022 0.41 0.00 0.00% 0.41 0.42 0.39
Nov 2, 2022 0.39 -0.05 -11.36% 0.44 0.45 0.39
Nov 1, 2022 0.45 0.04 9.76% 0.41 0.46 0.40
Oct 31, 2022 0.41 0.03 7.89% 0.38 0.44 0.38

Idera Pharma Events

Time (UTC) Country Event
Thursday, June 8, 2023

Time (UTC)

20:15

Country

US

Event

Q1 2023 Idera Pharmaceuticals Inc Earnings Release
Q1 2023 Idera Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Monday, August 7, 2023

Time (UTC)

10:59

Country

US

Event

Q2 2023 Idera Pharmaceuticals Inc Earnings Release
Q2 2023 Idera Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Monday, November 13, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Idera Pharmaceuticals Inc Earnings Release
Q3 2023 Idera Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 0 0 1.448 0.662 0.902
Revenue 0 0 1.448 0.662 0.902
Total Operating Expense 27.673 36.687 47.515 61.618 67.369
Selling/General/Admin. Expenses, Total 9.976 11.915 12.481 15.42 16.716
Research & Development 16.375 24.772 34.853 41.841 50.653
Operating Income -27.673 -36.687 -46.067 -60.956 -66.467
Interest Income (Expense), Net Non-Operating 6.961 0.134 0.516 1.075 0.483
Net Income Before Taxes 98.091 -112.662 -56.515 -59.881 -65.984
Net Income After Taxes 98.091 -112.662 -56.515 -59.881 -65.984
Net Income Before Extra. Items 98.091 -112.662 -56.515 -59.881 -65.984
Net Income 98.091 -112.662 -56.515 -59.881 -65.984
Total Adjustments to Net Income -1.15 0 -28.043
Income Available to Common Excl. Extra. Items 96.941 -112.662 -84.558 -59.881 -65.984
Income Available to Common Incl. Extra. Items 96.941 -112.662 -84.558 -59.881 -65.984
Diluted Net Income 96.941 -112.662 -84.558 -59.881 -65.984
Diluted Weighted Average Shares 50.127 33.821 28.545 26.601 19.6747
Diluted EPS Excluding Extraordinary Items 1.93391 -3.33113 -2.96227 -2.25108 -3.35374
Diluted Normalized EPS 1.96028 -3.33113 -2.95593 -2.08729 -3.35374
Total Extraordinary Items 0
Unusual Expense (Income) 1.322 0 0.181 4.357
Other, Net 118.803 -76.109 -10.964
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 0 0 0 0 0
Total Operating Expense 4.182 4.121 5.968 7.557 10.027
Selling/General/Admin. Expenses, Total 2.398 2.017 2.331 2.472 3.156
Research & Development 1.784 2.104 3.507 3.893 6.871
Operating Income -4.182 -4.121 -5.968 -7.557 -10.027
Interest Income (Expense), Net Non-Operating 0.004 0.002 0.003 -0.006 6.962
Other, Net 0 0 0 118.803
Net Income Before Taxes -4.178 -4.119 -5.965 -7.563 115.738
Net Income After Taxes -4.178 -4.119 -5.965 -7.563 115.738
Net Income Before Extra. Items -4.178 -4.119 -5.965 -7.563 115.738
Net Income -4.178 -4.119 -5.965 -7.563 115.738
Income Available to Common Excl. Extra. Items -4.178 -5.269 -5.965 -7.563 115.738
Income Available to Common Incl. Extra. Items -4.178 -5.269 -5.965 -7.563 115.738
Diluted Net Income -4.178 -5.269 -5.965 -7.563 115.738
Diluted Weighted Average Shares 52.893 52.842 52.74 49.909 70.98
Diluted EPS Excluding Extraordinary Items -0.07899 -0.09971 -0.1131 -0.15154 1.63057
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.07899 -0.09971 -0.11064 -0.12765 1.63057
Unusual Expense (Income) 0 0.13 1.192
Revenue 0
Total Adjustments to Net Income 0 -1.15
Dilution Adjustment 0
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 34.038 41.355 46.268 72.807 116.621
Cash and Short Term Investments 32.545 37.728 42.793 71.431 112.629
Cash & Equivalents 32.545 33.229 40.019 71.431 112.629
Short Term Investments 0 4.499 2.774 0
Prepaid Expenses 1.493 3.627 3.475 1.376 3.992
Total Assets 34.864 42.399 47.489 73.023 118.417
Property/Plant/Equipment, Total - Net 0.756 0.974 1.151 0.207 1.472
Property/Plant/Equipment, Total - Gross 1.553 1.807 1.925 0.871 5.932
Accumulated Depreciation, Total -0.797 -0.833 -0.774 -0.664 -4.46
Long Term Investments
Other Long Term Assets, Total 0.07 0.07 0.07 0.009 0.324
Total Current Liabilities 4.862 7.027 54.517 9.018 10.109
Accounts Payable 0.565 0.329 0.457 1.134 1.334
Accrued Expenses 4.297 6.263 7.624 7.884 8
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0 0 0.209
Other Current Liabilities, Total 0 0.435 46.436 0 0.566
Total Liabilities 5.411 133.571 58.657 9.029 10.722
Total Long Term Debt 0 0 0 0 0
Long Term Debt 0
Other Liabilities, Total 0.549 126.544 4.14 0.011 0.613
Total Equity 29.453 -91.172 -11.168 63.994 107.695
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.053 0.038 0.03 0.027 0.196
Additional Paid-In Capital 764.861 742.342 709.692 728.342 711.993
Retained Earnings (Accumulated Deficit) -735.461 -833.552 -720.89 -664.375 -604.494
Other Equity, Total 0
Total Liabilities & Shareholders’ Equity 34.864 42.399 47.489 73.023 118.417
Total Common Shares Outstanding 52.818 38.291 29.672 27.188 24.4531
Total Preferred Shares Outstanding 0.001 0.025 0.025 0.001 0.001
Redeemable Preferred Stock 0
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 29.362 34.038 38.299 43.475 47.018
Cash and Short Term Investments 27.993 32.545 36.602 40.59 44.541
Cash & Equivalents 27.993 32.545 36.602 40.59 44.541
Short Term Investments 0 0 0
Prepaid Expenses 1.369 1.493 1.697 2.885 2.477
Total Assets 30.133 34.864 39.18 44.411 48.008
Property/Plant/Equipment, Total - Net 0.701 0.756 0.811 0.866 0.92
Property/Plant/Equipment, Total - Gross 1.502 1.553 1.603 1.652 1.716
Accumulated Depreciation, Total -0.801 -0.797 -0.792 -0.786 -0.796
Other Long Term Assets, Total 0.07 0.07 0.07 0.07 0.07
Total Current Liabilities 3.796 4.862 5.566 6.029 4.996
Accounts Payable 0.24 0.565 0.276 0.184 0.185
Accrued Expenses 3.556 4.297 5.29 5.845 4.594
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0 0 0 0
Other Current Liabilities, Total 0 0 0 0.217
Total Liabilities 4.29 5.411 6.169 6.685 5.704
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.494 0.549 0.603 0.656 0.708
Total Equity 25.843 29.453 33.011 37.726 42.304
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.053 0.053 0.053 0.052 0.046
Additional Paid-In Capital 765.429 764.861 764.3 763.051 760.072
Retained Earnings (Accumulated Deficit) -739.639 -735.461 -731.342 -725.377 -717.814
Total Liabilities & Shareholders’ Equity 30.133 34.864 39.18 44.411 48.008
Total Common Shares Outstanding 52.924 52.818 52.777 52.115 46.537
Total Preferred Shares Outstanding 0.001 0.001 0.001 0.001 0.011
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line 98.091 -112.662 -56.515 -59.881 -65.984
Cash From Operating Activities -24.597 -33.772 -44.498 -51.916 -55.259
Cash From Operating Activities 0.022 0.061 0.12 0.432 0.746
Non-Cash Items -123.098 79.947 15.154 6.248 10.964
Cash Interest Paid 0.005 0 0 0.009 0.042
Changes in Working Capital 0.388 -1.118 -3.257 1.285 -0.985
Cash From Investing Activities 4.5 -1.687 -2.402 0.215 28.064
Capital Expenditures 0 -0.008 -0.011 -0.075 -0.206
Other Investing Cash Flow Items, Total 4.5 -1.679 -2.391 0.29 28.27
Cash From Financing Activities 19.413 28.669 15.488 10.192 59.157
Issuance (Retirement) of Stock, Net 19.848 28.886 5.422 10.409 59.46
Issuance (Retirement) of Debt, Net -0.435 -0.217 -0.006 -0.217 -0.303
Net Change in Cash -0.684 -6.79 -31.412 -41.509 31.962
Financing Cash Flow Items 0 10.072
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -4.178 98.091 102.21 108.175 115.738
Cash From Operating Activities -4.568 -24.597 -20.545 -15.85 -9.591
Cash From Operating Activities 0.004 0.022 0.017 0.011 0.006
Non-Cash Items 0.567 -123.098 -123.667 -124.142 -124.609
Cash Interest Paid 0 0.005 0.005 0.005 0.003
Changes in Working Capital -0.961 0.388 0.895 0.106 -0.726
Cash From Investing Activities 0 4.5 4.5 4.5 4.5
Capital Expenditures 0 0 0
Other Investing Cash Flow Items, Total 0 4.5 4.5 4.5 4.5
Cash From Financing Activities 0.016 19.413 19.418 18.711 16.403
Issuance (Retirement) of Stock, Net 0.016 19.848 19.853 19.146 16.621
Issuance (Retirement) of Debt, Net 0 -0.435 -0.435 -0.435 -0.218
Net Change in Cash -4.552 -0.684 3.373 7.361 11.312
Financing Cash Flow Items 0

Start a global, multi-asset portfolio with an award-winning platform

Desktop

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Idera Pharma Company profile

About Idera Pharmaceuticals Inc

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Idera Pharmaceuticals Inc revenues was not reported. Net income totaled $102.2M vs. loss of $36M. Net income reflects Future tranche right revaluation gain increase from $7M (expense) to $118.8M (income), Warrant revaluation gain increase from $188K to $7M (income), Research and development - Balancing decrease of 28% to $13.8M (expense).

Equity composition

Common Stock $.001 Par, 02/12, 70M auth., 27,637,007 issd., Insiders control 15.21%. IPO:2/96, 5,750,000 shs. @ $10 by Lehman Brothers. 12/97, 1-for-5 reverse split. FY'00 Q's are RES. 8/03 20,053,022 shs. issd. in a private placement. 9/05, 12/07, Company delisted from AMEX to NASDAQ.

Industry: Biotechnology & Medical Research (NEC)

505 Eagleview Boulevard
Suite 212
EXTON
PENNSYLVANIA 19341
US

Income Statement

  • Annual
  • Quarterly

People also watch

BTC/USD

26,428.50 Price
+0.120% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

US100

14,322.20 Price
+0.190% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 1.8

Oil - Crude

73.16 Price
+0.840% 1D Chg, %
Long position overnight fee -0.0156%
Short position overnight fee -0.0063%
Overnight fee time 21:00 (UTC)
Spread 0.03

Gold

1,947.25 Price
+0.370% 1D Chg, %
Long position overnight fee -0.0090%
Short position overnight fee 0.0008%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 535.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading